Conference
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
Abstract
Ispinesib (SB-715992) inhibits the mitotic kinesin spindle protein (KSP), a novel target for anticancer therapy. A phase II study was conducted to examine the efficacy of ispinesib in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSC). Patients with up to one prior line of chemotherapy for RMHNSC were treated with ispinesib 18 mg/m2 IV over 1 hour every 21 days. Twenty-one patients were enrolled onto this study with a target …
Authors
Tang PA; Siu LL; Chen EX; Hotte SJ; Chia S; Schwarz JK; Pond GR; Johnson C; Colevas AD; Synold TW
Volume
26
Pagination
pp. 257-264
Publisher
Springer Nature
Publication Date
6 2008
DOI
10.1007/s10637-007-9098-8
Conference proceedings
Investigational New Drugs
Issue
3
ISSN
0167-6997